Spyglass Pharma (NASDAQ:SGP) Stock: Insider Ra Capital Management, L.P. Buys 1,000 Shares

Spyglass Pharma, Inc. (NASDAQ:SGP – Get Free Report) Director Ra Capital Management, L.P. acquired 1,000 shares of the stock in a transaction that occurred on Monday, November 16th. The shares were bought at an average price of $32.43 per share, for a total transaction of $32,430.00. Following the transaction, the director owned 5,967,439 shares of the company’s stock, valued at $193,524,046.77. This trade represents a 0.02% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink.

Spyglass Pharma Stock Performance

Shares of SGP stock traded down $1.75 on Wednesday, reaching $29.68. The stock had a trading volume of 95,000 shares, compared to its average volume of 109,105. The stock has a market cap of $993.09 million and a P/E ratio of -3.84. Spyglass Pharma, Inc. has a 1 year low of $17.06 and a 1 year high of $39.92. The company has a 50 day simple moving average of $28.90 and a 200 day simple moving average of $24.90.

Spyglass Pharma (NASDAQ:SGP – Get Free Report) last announced its earnings results on Thursday, November 12th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.66) by ($0.07). On average, equities research analysts anticipate that Spyglass Pharma, Inc. will post -2.77 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Spyglass Pharma

A number of institutional investors and hedge funds have recently bought and sold shares of SGP. Bank of New York Mellon Corp purchased a new position in shares of Spyglass Pharma in the second quarter valued at about $533,000. Bank of America Corp DE purchased a new stake in shares of Spyglass Pharma during the first quarter worth about $726,000. The Manufacturers Life Insurance Company purchased a new stake in shares of Spyglass Pharma during the first quarter worth about $308,000. First Light Asset Management LLC purchased a new stake in shares of Spyglass Pharma during the first quarter worth about $9,716,000. Finally, Affinity Asset Advisors LLC bought a new stake in Spyglass Pharma during the 1st quarter valued at approximately $6,478,000.

Analyst Ratings Changes

SGP has been the subject of several recent research reports. UBS Group reissued a “buy” rating on shares of Spyglass Pharma in a report on Monday, October 5th. Weiss Ratings raised shares of Spyglass Pharma from a “sell (e)” rating to a “sell (d-)” rating in a report on Friday. Stifel Nicolaus raised their target price on shares of Spyglass Pharma from $42.00 to $44.00 and gave the stock a “buy” rating in a research note on Friday, November 13th. Wall Street Zen raised shares of Spyglass Pharma from a “sell” rating to a “hold” rating in a report on Saturday, October 31st. Finally, HC Wainwright upped their price target on shares of Spyglass Pharma from $37.00 to $43.00 and gave the stock a “buy” rating in a research report on Thursday, November 12th. Seven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Spyglass Pharma has an average rating of “Moderate Buy” and an average target price of $45.83.

View Our Latest Report on Spyglass Pharma

Spyglass Pharma Company Profile

(Get Free Report)

SpyGlass Pharma is a clinical-stage ophthalmology company developing sustained-release drug delivery systems for chronic eye diseases. Its research is focused on reducing reliance on patients’ regular use of eye drops. The company’s lead program is a bimatoprost drug delivery system being developed to treat glaucoma and ocular hypertension. Bimatoprost is a medication used to lower eye pressure, and SpyGlass is studying a delivery approach intended to provide treatment over an extended period. SpyGlass Pharma’s work centers on advancing this ophthalmic delivery platform and its lead program through clinical development.

See Also

Receive News & Ratings for Spyglass Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spyglass Pharma and related companies with MarketBeat.com's FREE daily email newsletter.